Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Penelope MacRae

Set Alert for Articles By Penelope MacRae

Latest From Penelope MacRae

Biocon’s Malaysia Insulin Plant Wins EU Clearance, Company Is Open To PE Investment

Biocon has received European regulatory clearance for its new Malaysian insulin plant and also said it is open to private-equity investment proposals for its fast-growing biologics division ahead of a planned IPO.

Two India Firms In Fresh FDA Trouble: Emcure Hit By Warning Letter, Dr Reddy’s Gets 483

The US regulator has slammed India’s Emcure Pharmaceuticals in a warning letter, accusing the company of slipshod investigation of tests showing microbial contamination and poor supervision, and has also sent a Form 483 containing eight observations to Dr Reddy’s.

Manufacturing Compliance

Natco Pivots To Emerging Markets To Drive Growth As Q1 Net Profit Slides

Indian company Natco said it is looking to emerging markets, including Brazil and China, to grow earnings as its first-quarter net profit dropped by a fifth in its financial first quarter.

Business Strategies Brazil

Lupin Q1 Profit Up 50% But Regulatory Overhang, Slow Product Scale-Up Sparks Concern

Lupin’s first-quarter net profit soared nearly 50%, but the strong performance was overshadowed by concerns about regulatory overhang and slower-than-expected scale-up of new products that could jeopardize future revenue growth momentum.

Manufacturing Business Strategies

Aurobindo Expects Sandoz Completion ‘Very Soon’

Aurobindo Pharma says its billion-dollar purchase of Sandoz’s US business is on track for completion “very soon” as it announced net first-quarter net profit that rocketed by nearly 40%, powered by strong US sales.

Deals Sales & Earnings

Mallinckrodt Delays Generics Spinoff

Mallinckrodt has put on hold its plan to spin off its specialty generics business due to investor worries about potentially big payouts arising from ongoing US opioids litigation.

Strategy Generic Drugs
See All